Advagene Biopharma Co. Ltd.
1 marketed ·
Quick facts
Marketed products
Phase 2 pipeline
- AD07010 · Oncology
AD07010 is a small molecule that targets the PI3K/AKT/mTOR pathway. - AD17002
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: